Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cidara Thera (CDTX)

Cidara Thera (CDTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 56,064
  • Shares Outstanding, K 4,562
  • Annual Sales, $ 64,290 K
  • Annual Income, $ -29,800 K
  • 60-Month Beta 0.98
  • Price/Sales 0.73
  • Price/Cash Flow N/A
  • Price/Book 5.77
Trade CDTX with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 144.84%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 1,384.86% on 02/09/24
  • IV Low 0.00% on 04/25/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 42
  • Volume Avg (30-Day) 159
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 7,932
  • Open Int (30-Day) 3,713

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.07
  • Number of Estimates 1
  • High Estimate -0.07
  • Low Estimate -0.07
  • Prior Year 0.03
  • Growth Rate Est. (year over year) -333.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.00 +27.25%
on 04/23/24
24.40 -47.83%
on 04/03/24
-2.20 (-14.72%)
since 03/25/24
3-Month
10.00 +27.25%
on 04/23/24
24.40 -47.83%
on 04/03/24
-0.77 (-5.70%)
since 01/25/24
52-Week
10.00 +27.25%
on 04/23/24
29.60 -56.99%
on 05/23/23
-7.87 (-38.20%)
since 04/25/23

Most Recent Stories

More News
Stocks Plunge Before the Open as Meta’s Revenue Forecast Disappoints, U.S. GDP Data and Earnings in Focus

June S&P 500 E-Mini futures (ESM24) are down -0.53%, and June Nasdaq 100 E-Mini futures (NQM24) are down -0.87% this morning as a disappointing revenue outlook for the current quarter from Meta weighed...

ESM24 : 5,085.25 (-0.44%)
NQM24 : 17,582.25 (-0.47%)
META : 440.00 (-10.84%)
TSLA : 168.92 (+4.19%)
HAS : 64.92 (-0.17%)
TXN : 175.78 (+0.55%)
ODFL : 197.26 (+1.13%)
MSFT : 398.84 (-2.50%)
GOOGL : 155.76 (-2.12%)
MRK : 130.92 (+3.09%)
GILD : 65.15 (-2.88%)
CAT : 339.82 (-6.52%)
Cidara Therapeutics: Q3 Earnings Snapshot

Cidara Therapeutics: Q3 Earnings Snapshot

CDTX : 12.97 (+5.53%)
Cidara Therapeutics: Q2 Earnings Snapshot

Cidara Therapeutics: Q2 Earnings Snapshot

CDTX : 12.97 (+5.53%)
Cidara Therapeutics: Q1 Earnings Snapshot

Cidara Therapeutics: Q1 Earnings Snapshot

CDTX : 12.97 (+5.53%)
Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates

Merus N.V. (MRUS) delivered earnings and revenue surprises of 19.63% and 27.76%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

MRUS : 44.99 (+7.20%)
CDTX : 12.97 (+5.53%)
Are Options Traders Betting on a Big Move in Cidara (CDTX) Stock?

Investors need to pay close attention to Cidara (CDTX) stock based on the movements in the options market lately.

CDTX : 12.97 (+5.53%)
Cidara Therapeutics (CDTX) Reports Q4 Loss, Misses Revenue Estimates

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -1,800% and 45.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

CDTX : 12.97 (+5.53%)
CRMD : 5.18 (-2.81%)
Cidara Therapeutics: Q4 Earnings Snapshot

Cidara Therapeutics: Q4 Earnings Snapshot

CDTX : 12.97 (+5.53%)
Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO™ (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis

Cidara Therapeutics, Inc. (Nasdaq: CDTX) and Melinta Therapeutics, LLC today announced that the U.S. Food and Drug Administration (FDA) approved REZZAYO™ (rezafungin for injection) for the treatment...

CDTX : 12.97 (+5.53%)
Horizon Therapeutics (HZNP) Q4 Earnings and Revenues Top Estimates

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 11.01% and 1.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

HZNP : 116.30 (+0.04%)
CDTX : 12.97 (+5.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company...

See More

Key Turning Points

3rd Resistance Point 15.70
2nd Resistance Point 14.15
1st Resistance Point 13.22
Last Price 12.97
1st Support Level 10.73
2nd Support Level 9.18
3rd Support Level 8.25

See More

52-Week High 29.60
Fibonacci 61.8% 22.11
Fibonacci 50% 19.80
Fibonacci 38.2% 17.49
Last Price 12.97
52-Week Low 10.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar